ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,277.51
0.80%
Dow Jones
38,686.32
1.51%
US Dollar vs MXN
17.04159
0.00%
Brent Oil
81.295
0.00%
Bitcoin
67,605.79
0.18%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. aTyr Pharma Inc (LIFE)

  7. aTyr Pharma Inc (LIFE) Noticias

LIFE

aTyr Pharma (LIFE)

aTyr Pharma Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:LIFE
FechaHoraFuenteTítuloSímboloCompañía
29/05/202415:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIFEaTyr Pharma Inc
24/05/202415:00GlobeNewswire Inc.aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:LIFEaTyr Pharma Inc
23/05/202418:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIFEaTyr Pharma Inc
15/05/202406:00GlobeNewswire Inc.aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International ConferenceNASDAQ:LIFEaTyr Pharma Inc
14/05/202407:00GlobeNewswire Inc.aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary SarcoidosisNASDAQ:LIFEaTyr Pharma Inc
06/05/202407:00GlobeNewswire Inc.aTyr Pharma to Present at Upcoming Investor ConferencesNASDAQ:LIFEaTyr Pharma Inc
02/05/202415:00GlobeNewswire Inc.aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate UpdateNASDAQ:LIFEaTyr Pharma Inc
01/04/202407:00GlobeNewswire Inc.aTyr Pharma to Participate in April Investor ConferencesNASDAQ:LIFEaTyr Pharma Inc
14/03/202415:00GlobeNewswire Inc.aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate UpdateNASDAQ:LIFEaTyr Pharma Inc
28/02/202407:00GlobeNewswire Inc.aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial ResultsNASDAQ:LIFEaTyr Pharma Inc
21/02/202407:00GlobeNewswire Inc.aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial ParticipantsNASDAQ:LIFEaTyr Pharma Inc
29/01/202407:00GlobeNewswire Inc.aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell DiversityNASDAQ:LIFEaTyr Pharma Inc
18/01/202407:00GlobeNewswire Inc.aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as AdvisorNASDAQ:LIFEaTyr Pharma Inc
02/01/202411:21Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:LIFEaTyr Pharma Inc
20/11/202323:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LIFEaTyr Pharma Inc
13/11/202307:00GlobeNewswire Inc.aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023NASDAQ:LIFEaTyr Pharma Inc
09/11/202316:01Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:LIFEaTyr Pharma Inc
09/11/202315:42Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:LIFEaTyr Pharma Inc
09/11/202315:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LIFEaTyr Pharma Inc
09/11/202315:00GlobeNewswire Inc.aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate UpdateNASDAQ:LIFEaTyr Pharma Inc
01/11/202307:00GlobeNewswire Inc.aTyr Pharma to Present at November Investor ConferencesNASDAQ:LIFEaTyr Pharma Inc
31/10/202307:00GlobeNewswire Inc.aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Patients with SSc-ILDNASDAQ:LIFEaTyr Pharma Inc
11/09/202307:00GlobeNewswire Inc.aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported OutcomesNASDAQ:LIFEaTyr Pharma Inc
24/08/202307:00GlobeNewswire Inc.aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:LIFEaTyr Pharma Inc
10/08/202315:07Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:LIFEaTyr Pharma Inc
09/08/202315:00GlobeNewswire Inc.aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate UpdateNASDAQ:LIFEaTyr Pharma Inc
22/06/202307:00GlobeNewswire Inc.European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of Systemic SclerosisNASDAQ:LIFEaTyr Pharma Inc
20/06/202307:00GlobeNewswire Inc.aTyr Pharma to Present on Lead Therapeutic Candidate Efzofitimod at the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) ConferenceNASDAQ:LIFEaTyr Pharma Inc
06/06/202307:00GlobeNewswire Inc.aTyr Pharma to Highlight Advancements in tRNA Synthetase Biology Research at the 13th International Symposium of Aminoacyl-tRNA Synthetases (AARS 2023)NASDAQ:LIFEaTyr Pharma Inc
25/05/202307:00GlobeNewswire Inc.aTyr Pharma to Present at the 2023 Jefferies Healthcare ConferenceNASDAQ:LIFEaTyr Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:LIFE

Su Consulta Reciente

BIT
P1TG29
NLBNPIT1TG29 20240621 70
BIT
P1XCT9
NLBNPIT1XCT9 20240621 1....
BIT
P20A67
NLBNPIT20A67 20240621 34...
BIT
P1YAT1
NLBNPIT1YAT1 20991231 10...
LBNK
K21USDT
k21.kanon.art
NYSE
LUMN
Lumen Technologies
NASDAQ
INTU
Intuit
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados